Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hang Lung Group Ltd. stock logo
HNLGY
Hang Lung Group
$8.17
$7.59
$5.28
$8.28
$7.35B0.1377 shsN/A
Jiangsu Expressway Co. stock logo
JEXYY
Jiangsu Expressway
$29.00
+4.7%
$25.89
$18.29
$29.00
N/A0.2271 shs3 shs
Omron Corp. stock logo
OMRNY
Omron
$27.79
+5.9%
$26.91
$24.16
$47.75
$5.41B1.0445,139 shs70,882 shs
Pharma Mar stock logo
PHMMF
Pharma Mar
$92.57
$93.16
$34.26
$105.60
N/A0.22,411 shs3,808 shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hang Lung Group Ltd. stock logo
HNLGY
Hang Lung Group
0.00%0.00%+11.93%+26.97%+44.61%
Jiangsu Expressway Co. stock logo
JEXYY
Jiangsu Expressway
0.00%0.00%+18.66%+18.85%+41.53%
Omron Corp. stock logo
OMRNY
Omron
+7.72%-0.04%+3.34%-2.53%-26.66%
Pharma Mar stock logo
PHMMF
Pharma Mar
0.00%0.00%-10.65%+4.97%+170.20%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Hang Lung Group Ltd. stock logo
HNLGY
Hang Lung Group
N/AN/AN/AN/AN/AN/AN/AN/A
Jiangsu Expressway Co. stock logo
JEXYY
Jiangsu Expressway
N/AN/AN/AN/AN/AN/AN/AN/A
Omron Corp. stock logo
OMRNY
Omron
2.3938 of 5 stars
0.05.01.70.00.50.02.5
Pharma Mar stock logo
PHMMF
Pharma Mar
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Hang Lung Group Ltd. stock logo
HNLGY
Hang Lung Group
0.00
N/AN/AN/A
Jiangsu Expressway Co. stock logo
JEXYY
Jiangsu Expressway
0.00
N/AN/AN/A
Omron Corp. stock logo
OMRNY
Omron
0.00
N/AN/AN/A
Pharma Mar stock logo
PHMMF
Pharma Mar
4.00
Strong BuyN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Hang Lung Group Ltd. stock logo
HNLGY
Hang Lung Group
$1.51B4.88$0.35 per share23.47$20.09 per share0.41
Jiangsu Expressway Co. stock logo
JEXYY
Jiangsu Expressway
N/AN/AN/AN/AN/AN/A
Omron Corp. stock logo
OMRNY
Omron
$5.26B1.09$1.68 per share16.52$29.90 per share0.93
Pharma Mar stock logo
PHMMF
Pharma Mar
$189.23MN/A$0.41 per share223.50$11.62 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Hang Lung Group Ltd. stock logo
HNLGY
Hang Lung Group
$276.02MN/A0.00N/AN/AN/AN/A7/28/2025 (Estimated)
Jiangsu Expressway Co. stock logo
JEXYY
Jiangsu Expressway
N/AN/A0.00N/AN/AN/AN/A8/27/2025 (Estimated)
Omron Corp. stock logo
OMRNY
Omron
$107.39M$0.5649.6317.59N/A2.07%1.75%1.22%8/1/2025 (Estimated)
Pharma Mar stock logo
PHMMF
Pharma Mar
$28.27MN/A0.00N/AN/AN/AN/A7/28/2025 (Estimated)

Latest PHMMF, HNLGY, JEXYY, and OMRNY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q4 2025
Omron Corp. stock logo
OMRNY
Omron
$0.4052$0.30-$0.1052$0.30$1.48 billion$1.53 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Hang Lung Group Ltd. stock logo
HNLGY
Hang Lung Group
$0.799.67%N/AN/AN/A
Jiangsu Expressway Co. stock logo
JEXYY
Jiangsu Expressway
$1.214.17%N/AN/AN/A
Omron Corp. stock logo
OMRNY
Omron
$0.612.20%N/A108.93%N/A
Pharma Mar stock logo
PHMMF
Pharma Mar
N/AN/AN/AN/AN/A

Latest PHMMF, HNLGY, JEXYY, and OMRNY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/1/2025
Jiangsu Expressway Co. stock logo
JEXYY
Jiangsu Expressway
$1.20834.17%7/3/20257/4/20258/11/2025
5/2/2025
Hang Lung Group Ltd. stock logo
HNLGY
Hang Lung Group
$0.39917.39%5/8/20255/9/20256/26/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Hang Lung Group Ltd. stock logo
HNLGY
Hang Lung Group
0.34
0.71
0.71
Jiangsu Expressway Co. stock logo
JEXYY
Jiangsu Expressway
N/AN/AN/A
Omron Corp. stock logo
OMRNY
Omron
0.13
2.31
1.57
Pharma Mar stock logo
PHMMF
Pharma Mar
0.20
2.97
2.33

Institutional Ownership

CompanyInstitutional Ownership
Hang Lung Group Ltd. stock logo
HNLGY
Hang Lung Group
N/A
Jiangsu Expressway Co. stock logo
JEXYY
Jiangsu Expressway
N/A
Omron Corp. stock logo
OMRNY
Omron
1.09%
Pharma Mar stock logo
PHMMF
Pharma Mar
N/A

Insider Ownership

CompanyInsider Ownership
Hang Lung Group Ltd. stock logo
HNLGY
Hang Lung Group
N/A
Jiangsu Expressway Co. stock logo
JEXYY
Jiangsu Expressway
N/A
Omron Corp. stock logo
OMRNY
Omron
N/A
Pharma Mar stock logo
PHMMF
Pharma Mar
1.88%
CompanyEmployeesShares OutstandingFree FloatOptionable
Hang Lung Group Ltd. stock logo
HNLGY
Hang Lung Group
3,930899.85 millionN/ANot Optionable
Jiangsu Expressway Co. stock logo
JEXYY
Jiangsu Expressway
4,754N/AN/ANot Optionable
Omron Corp. stock logo
OMRNY
Omron
28,450206.24 millionN/ANot Optionable
Pharma Mar stock logo
PHMMF
Pharma Mar
509N/AN/ANot Optionable

Recent News About These Companies

Pharma Mar’s Strategic Shareholder Meeting
ASCO 25: Jazz, PharmaMar reveal SCLC survival data
Exploring High Growth Tech Stocks In Europe May 2025
Exploring High Growth Tech Stocks in Europe April 2025
Pharma Mar Releases 2024 Director Remuneration Report
High Growth Tech Leads These 3 Top Stocks with Potential
3 Stocks Estimated To Be Up To 48% Below Intrinsic Value
Insider-Led Growth Stocks To Watch In December 2024
Pharma Mar S.A. Reduces Share Capital by Canceling Shares
Pharma Mar Achieves Legal Win in Aplidin Case
PharmaMar gets $10 million milestone from Janssen for Yondelis

New MarketBeat Followers Over Time

Media Sentiment Over Time

Hang Lung Group stock logo

Hang Lung Group OTCMKTS:HNLGY

$8.17 0.00 (0.00%)
As of 07/7/2025

Hang Lung Group Limited, an investment holding company, operates as a property developer in Hong Kong and the Mainland of China. The company operates through Property Leasing and Property Sales segments. It develops properties for sale and lease, such as large-scale commercial, office, and residential developments. The company also invests in and develops various properties, including shopping malls, office premises, residential and industrial premises, and car parking bays. In addition, its investment properties portfolio includes Grand Gateway 66, a commercial, office, and residential complex, as well as Plaza 66, a commercial and office complex in Shanghai; Palace 66 and Forum 66 in Shenyang; Parc 66 in Jinan; Center 66 in Wuxi; Riverside 66 in Tianjin; Olympia 66 in Dalian; Spring City 66 in Kunming; and Heartland 66 in Wuhan. Further, the company offers car park and property management, financial, management, project management, and property agency services, as well as operates and manages apartment. Hang Lung Group Limited was incorporated in 1960 and is headquartered in Central, Hong Kong.

Jiangsu Expressway stock logo

Jiangsu Expressway OTCMKTS:JEXYY

$29.00 +1.30 (+4.71%)
As of 07/3/2025

Jiangsu Expressway Company Limited engages in investment, construction, operation, and management of toll roads and bridges in the People's Republic of China. The company operates the Jiangsu section of Shanghai-Nanjing Expressway, Ningchang Expressway, Zhenli Expressway, Guangjing Expressway, Xicheng Expressway, Xiyi Expressway, Zhendan Expressway, Yanjiang Expressway, Jiangyin Bridge, Sujiahang Expressway, Changyi Expressway, Yichang Expressway, and Wufengshan Bridge. As of December 31, 2022, it operated 17 road and bridge projects; and owned approximately 910 kilometers of roads and bridges. The company also offers passenger transportation; and ancillary services, including refueling, catering, shopping, automobile maintenance, advertising and accommodation, etc. In addition, it engages in the real estate development; and sale of electricity and petroleum products. The company was incorporated in 1992 and is headquartered in Nanjing, China. Jiangsu Expressway Company Limited is a subsidiary of JiangSu Communications Holding Co., Ltd.

Omron stock logo

Omron OTCMKTS:OMRNY

$27.79 +1.55 (+5.91%)
As of 03:52 PM Eastern

OMRON Corporation engages in industrial automation, device and module solutions, social systems, and healthcare businesses worldwide. The Industrial Automation Business offers sensors, switches, safety and control components, relays, motion and drives, robotics, energy conservation, power supplies, and automation system products. It also offers environmental mobility, digital devices, food and commodity, logistic and warehouse automation, medical, robotic, panel, vision, software, and traceability related solutions. The Social Systems, Solutions and Service Business provides energy, public transport, traffic safety, network protection, payment, infrastructure monitoring, management service, and DX solutions, as well as offers remote surveillance/monitoring, automation/robotics, software development, engineering/maintenance, and other services. The Healthcare Business provides cardiovascular, respiratory care, pain management, remote patient monitoring, and other solutions. The Device and Module Solutions Business offers relays, switches, connectors, and sensors. OMRON Corporation was founded in 1933 and is headquartered in Kyoto, Japan.

Pharma Mar stock logo

Pharma Mar OTCMKTS:PHMMF

$92.57 0.00 (0.00%)
As of 07/8/2025

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.